| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Acetylcholinesterase (AChE).
|
|---|---|
| ln Vitro |
Memogain is an inactive pro-drug of galantamine. It is cleaved by brain carboxyesterases to release the active drug galantamine, which inhibits acetylcholinesterase (AChE). By inhibiting AChE, it increases acetylcholine levels in the brain, improving cognitive function.
|
| ln Vivo |
In vivo, Memogain is converted to galantamine in the brain, providing acetylcholinesterase inhibition. It has been studied for the treatment of Alzheimer's disease, with the goal of reducing adverse effects and enhancing efficacy compared to galantamine.
|
| Enzyme Assay |
Memogain is evaluated in cell-free assays for acetylcholinesterase inhibition after conversion to galantamine. The compound is incubated with brain homogenates or purified carboxyesterases to generate galantamine, and AChE activity is measured using colorimetric or fluorometric methods.
|
| Cell Assay |
Memogain is assessed in cell-based assays using neuronal cell lines. Cells are treated with Memogain, and the conversion to galantamine and subsequent AChE inhibition are measured. Acetylcholine levels and neuronal activity may also be assessed.
|
| Animal Protocol |
Memogain is administered orally in animal models of Alzheimer's disease to evaluate its efficacy in improving cognitive function. Efficacy is assessed using behavioral tests (e.g., Morris water maze) and by measuring AChE activity and acetylcholine levels in the brain.
|
| ADME/Pharmacokinetics |
No detailed PK data available. Memogain has a molecular weight of 391.46.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data available. Memogain is designed to have reduced adverse effects compared to galantamine. For research use only.
|
| References | |
| Additional Infomation |
Memogain (GLN-1062) is a pro-drug of galantamine. Molecular formula: C24H25NO4; MW: 391.46. Used in Alzheimer's disease research. For research use only.
|
| Molecular Formula |
C24H25NO4
|
|---|---|
| Molecular Weight |
391.467
|
| Exact Mass |
391.178
|
| CAS # |
224169-27-1
|
| PubChem CID |
44240142
|
| Appearance |
White to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
523.2±50.0 °C at 760 mmHg
|
| Flash Point |
270.2±30.1 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.642
|
| LogP |
4.33
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
645
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
O1C2=C(C([H])=C([H])C3C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])[C@]4(C([H])=C([H])[C@@]([H])(C([H])([H])[C@]14[H])OC(C1C([H])=C([H])C([H])=C([H])C=1[H])=O)C2=3)OC([H])([H])[H]
|
| InChi Key |
JKVNJTYHRABHIY-WXVUKLJWSA-N
|
| InChi Code |
InChI=1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3/t18-,20-,24-/m0/s1
|
| Chemical Name |
[(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-yl] benzoate
|
| Synonyms |
GLN-1062; GLN-1062; Memogain
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~255.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.39 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5545 mL | 12.7724 mL | 25.5447 mL | |
| 5 mM | 0.5109 mL | 2.5545 mL | 5.1089 mL | |
| 10 mM | 0.2554 mL | 1.2772 mL | 2.5545 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
